IMTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Immatics N.V.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 5, 2026
$7.05+0.32 (+4.75%)
Close on Oct 19, 2026
Ownership
Who owns Immatics's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
1 buys · 0 sales
Net bought $7.50M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Felix J. Baker | 9,508,565 | 7.00% | 13G (passive) amendment | Jun 30, 2026 |
| Suvretta Capital Management, LLC | 9,135,029 | 7.50% | 13G (passive) amendment | Mar 31, 2025 |
| RTW Investments, LP | 8,815,617 | 7.30% | 13G (passive) amendment | Sep 30, 2025 |
| Wellington Group Holdings LLP | 8,583,568 | 7.10% | 13G (passive) amendment | Mar 31, 2025 |
| The Toronto-Dominion Bank | 7,436,342 | 5.50% | 13G (passive) | Mar 31, 2026 |
| Baker Bros. Advisors (GP) LLC | 7,275,830 | 6.00% | 13G (passive) amendment | Dec 31, 2024 |
| Roderick Wong, M.D. | 6,540,540 | 5.50% | 13G (passive) amendment | Dec 31, 2024 |
| T. Rowe Price Investment Management, Inc. | 21,652,162 | 16.10% | 13G (passive) amendment | Mar 31, 2026 |
| Roderick Wong | 12,869,340 | 9.60% | 13G (passive) amendment | Mar 31, 2026 |
| Joseph Edelman | 11,418,016 | 7.60% | 13D (active) amendment | Aug 26, 2026 |
| Aaron Cowen | 11,190,129 | 8.30% | 13G (passive) amendment | Dec 31, 2025 |
| Baker Bros. Advisors LP | 10,168,901 | 8.40% | 13G (passive) amendment | Jun 30, 2025 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jasuja Harpreet Singh | Chief Executive Officer, Director | 217,241 | 0.16% | Mar 18, 2026 |
| James Nelson Pepin | Gen Counsel and Corp Secretary | – | – | Aug 18, 2026 |
| Jordan Zeik Silverstein | Head of Strategy | 7,826 | 0.01% | Mar 18, 2026 |
| Cedrik Michael Britten | Chief Medical Officer | 250 | 0.00% | Mar 18, 2026 |
| Amie Elizabeth Krause | Chief People Officer | – | – | Mar 18, 2026 |
| Carsten Alexander Johannes Reinhardt | Chief Development Officer | 47,781 | 0.04% | Mar 18, 2026 |
| Steffen Martin Walter | Chief Operating Officer | 10,000 | 0.01% | Mar 18, 2026 |
| Venkat Ramanan | Chief Financial Officer | – | – | Mar 18, 2026 |
| Rainer Kramer | Chief Business Officer | – | – | Mar 18, 2026 |
| Toni Michael Weinschenk | Chief Innovation Officer | – | – | Mar 18, 2026 |
| Edward A. Sturchio Jr | General Counsel | – | – | Mar 18, 2026 |
| Advisors Llc Perceptive | Director | – | – | Aug 27, 2026 |
| Joseph Edelman | Director | 11,246,516 | 8.39% | Aug 27, 2026 |
| Life Sciences Master Fund Ltd Perceptive | Director | – | – | Aug 27, 2026 |
| Alise Reicin | Director | – | – | Jun 18, 2026 |
| Eliot Forster | Director | – | – | Jun 18, 2026 |
| Michael G. Atieh | Director | – | – | Jun 18, 2026 |
| Heather L. Mason | Director | – | – | Jun 18, 2026 |
| Paul Rutherford Carter | Director | – | – | Jun 18, 2026 |
| Peter Alan Chambre | Director | 105,987 | 0.08% | Jun 18, 2026 |
| Mathias Hothum | Director | 329,521 | 0.25% | Jun 18, 2026 |
| Adam Leo Stone | Director | – | – | Jun 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Joseph Edelman Director | Aug 26, 2026 | Buy | +863,060 | $8.69 | $7.50M | 11,246,516 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.